Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Shapiro

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 14, 2006
Lead, genetic susceptibility, and risk of adult brain tumorsPreetha Rajaraman, Patricia A Stewart, Jonathan M Samet, et al.
Neuro-Oncology|May 8, 2012
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survivalLeland S Hu, Jennifer M Eschbacher, Joseph E Heiserman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end pointsMinesh P Mehta, William R Shapiro, Michael J Glantz, et al.
Neurosurgery|August 17, 2002
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustineRobert G Selker, William R Shapiro, Peter Burger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeDavid A Reardon, Karen L Fink, Tom Mikkelsen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 4, 2008
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trialMinesh P Mehta, William R Shapiro, See C Phan, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 14, 2006
Lead, genetic susceptibility, and risk of adult brain tumorsPreetha Rajaraman, Patricia A Stewart, Jonathan M Samet, et al.
Neuro-Oncology|May 8, 2012
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survivalLeland S Hu, Jennifer M Eschbacher, Joseph E Heiserman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end pointsMinesh P Mehta, William R Shapiro, Michael J Glantz, et al.
Neurosurgery|August 17, 2002
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustineRobert G Selker, William R Shapiro, Peter Burger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeDavid A Reardon, Karen L Fink, Tom Mikkelsen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 4, 2008
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trialMinesh P Mehta, William R Shapiro, See C Phan, et al.
Pageof 4